Numerous clinical trials spanning Early Phase 1 to Phase 4 evaluate carbamazepine across completed, active, recruiting, and not yet recruiting statuses. Sponsored by pharmaceutical leaders and academic medical centers, these studies investigate neurological conditions such as focal epilepsy and trigeminal neuralgia, substance-related disorders, and pharmacokinetics in healthy participants and patients with advanced non-small cell lung cancer.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07673549 | NOT_YET_RECRUITING | Idiopathic Trigeminal Neuralgia |
Beijing Tiantan Hospital |
2026-08-31 | |
| NCT03307863 | SUSPENDED | Contraception; Drug Interactions |
University of Sao Paulo |
2017-11-01 | PHASE4 |
| NCT07750730 | NOT_YET_RECRUITING | Trigeminal Neuralgia (TN) |
Beijing Hospital of Traditional Chinese Medicine |
2026-08-31 | |
| NCT07369622 | NOT_YET_RECRUITING | Gout Initiating Urate-loweringUrate-lowering Therapy; Gout Arthritis; Gout and Hyperuricemia |
Haiphong University of Medicine and Pharmacy |
2026-01-20 | PHASE4 |
| NCT07395024 | ACTIVE_NOT_RECRUITING | Healthy Volunteer |
Astellas Pharma Global Development, Inc. |
2026-02-03 | PHASE1 |
| NCT07781631 | NOT_YET_RECRUITING | Healthy |
Boehringer Ingelheim |
2026-09-10 | PHASE1 |
| NCT07766369 | NOT_YET_RECRUITING | Healthy Volunteers |
Eisai Inc. |
2026-08-12 | PHASE1 |
| NCT07446400 | RECRUITING | Healthy Volunteers |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2026-03-31 | PHASE1 |
| NCT07775261 | NOT_YET_RECRUITING | Healthy Participants |
H. Lundbeck A/S |
2026-08-27 | PHASE1 |
| NCT07570082 | COMPLETED | Healthy Volunteers |
Crinetics Pharmaceuticals Inc. |
2026-05-28 | PHASE1 |
| NCT06909162 | COMPLETED | Healthy Participants |
Incyte Corporation |
2025-05-05 | PHASE1 |
| NCT07449390 | COMPLETED | Healthy Participants |
Acesion Pharma |
2026-04-01 | PHASE1 |
| NCT07279233 | COMPLETED | Healthy; Volunteer |
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany |
2025-12-15 | PHASE1 |
| NCT07198035 | COMPLETED | Healthy Adults |
Pfizer |
2025-09-18 | PHASE1 |
| NCT07252453 | ACTIVE_NOT_RECRUITING | Trigeminal Neuralgia |
Abbasi Shaheed Hospital |
2025-05-20 | |
| NCT07100964 | COMPLETED | Healthy |
Boehringer Ingelheim |
2025-08-11 | PHASE1 |
| NCT06547164 | COMPLETED | Healthy Participants |
AstraZeneca |
2024-08-27 | PHASE1 |
| NCT06965881 | TERMINATED | Tuberous Sclerosis Complex (TSC); Focal Cortical Dysplasia; Other Neurological Disorders |
GRIN Therapeutics, Inc. |
2025-05-08 | PHASE1 |
| NCT06672900 | ACTIVE_NOT_RECRUITING | Healthy Volunteer |
Aligos Therapeutics |
2025-01-09 | PHASE1 |
| NCT06847464 | COMPLETED | RSV Infection; Drug Drug Interaction (DDI) |
Enanta Pharmaceuticals, Inc |
2025-01-27 | PHASE1 |
| NCT06914869 | COMPLETED | Healthy Participants |
X4 Pharmaceuticals |
2025-02-18 | PHASE1 |
| NCT06897683 | COMPLETED | Healthy Adults |
Pfizer |
2025-03-21 | PHASE1 |
| NCT06751017 | COMPLETED | COVID-19 |
Shionogi |
2024-12-17 | PHASE1 |
| NCT06671405 | COMPLETED | Dyslipidaemia |
AstraZeneca |
2024-09-25 | PHASE1 |
| NCT06633419 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2024-12-18 | PHASE1 |
| NCT06596668 | COMPLETED | Healthy |
Merck Sharp & Dohme LLC |
2024-10-02 | PHASE1 |
| NCT06357260 | UNKNOWN | Trigeminal Neuralgia |
Postgraduate Institute of Dental Sciences Rohtak |
2024-04-01 | |
| NCT06849219 | ACTIVE_NOT_RECRUITING | Trigeminal Neuralgia |
Jinnah Postgraduate Medical Centre |
2024-09-21 | PHASE4 |
| NCT06646042 | COMPLETED | Healthy |
Pfizer |
2024-10-28 | PHASE1 |
| NCT06370728 | COMPLETED | Healthy |
Eli Lilly and Company |
2024-05-06 | PHASE1 |
| NCT07304453 | COMPLETED | Trigeminal Neuralgia; Neuropathic Pain |
Karbala University |
2024-01-07 | PHASE2 |
| NCT03689114 | COMPLETED | Epilepsies, Partial |
Mario Negri Institute for Pharmacological Research |
2021-05-10 | PHASE4 |
| NCT06345794 | COMPLETED | Healthy |
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company |
2024-04-03 | PHASE1 |
| NCT05419180 | COMPLETED | Pharmacoresistant Focal Epilepsies |
Biocodex |
2022-10-13 | PHASE4 |
| NCT06348888 | COMPLETED | Advanced Non-small Cell Lung Cancer; EGFR Mutation; HER2 Mutation; Healthy Volunteers |
Bayer |
2024-04-10 | PHASE1 |
| NCT06173596 | COMPLETED | Healthy |
Alexion Pharmaceuticals, Inc. |
2024-01-10 | PHASE1 |
| NCT05840952 | COMPLETED | COVID-19 |
Aligos Therapeutics |
2023-07-04 | PHASE1 |
| NCT06071442 | COMPLETED | Healthy Participants |
Alexion Pharmaceuticals, Inc. |
2024-01-17 | PHASE1 |
| NCT06357260 | Not yet recruiting | Trigeminal Neuralgia |
Postgraduate Institute of Dental Sciences Rohtak |
2024-04 | Not Applicable |
| NCT06348888 | Recruiting | Advanced Non-small Cell Lung Cancer|EGFR Mutation|HER2 Mutation|Healthy Volunteers |
Bayer |
2024-04-10 | Phase 1 |
| NCT06028464 | COMPLETED | Healthy |
Boehringer Ingelheim |
2023-09-11 | PHASE1 |
| NCT05965219 | COMPLETED | Healthy Volunteers |
Cerevel Therapeutics, LLC |
2023-08-15 | PHASE1 |
| NCT05932303 | COMPLETED | Healthy Participants |
Bristol-Myers Squibb |
2023-07-12 | PHASE1 |
| NCT06005688 | COMPLETED | Healthy Participants |
Pfizer |
2023-08-18 | PHASE1 |
| NCT05748236 | UNKNOWN | Focal Epilepsy |
Dhaka Medical College |
2022-11-01 | PHASE4 |
| NCT05994807 | COMPLETED | Healthy Volunteers |
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company |
2023-08-08 | PHASE1 |
| NCT05860933 | COMPLETED | Healthy |
Eli Lilly and Company |
2023-05-08 | PHASE1 |
| NCT06005688 | Completed | Healthy Participants |
Pfizer|Arvinas Estrogen Receptor Inc. |
2023-08-18 | Phase 1 |
| NCT05824143 | COMPLETED | Healthy Participants |
Cerevel Therapeutics, LLC |
2023-04-17 | PHASE1 |
| NCT05860933 | Completed | Healthy |
Eli Lilly and Company|Loxo Oncology Inc. |
2023-05-08 | Phase 1 |
| NCT05552196 | COMPLETED | Healthy |
Janssen Pharmaceutica N.V., Belgium |
2022-10-18 | PHASE1 |
| NCT06316362 | COMPLETED | Acute Poisoning |
Alexandria University |
2022-01-01 | PHASE2 |
| NCT05581823 | COMPLETED | Parkinson Disease |
Cerevel Therapeutics, LLC |
2022-10-19 | PHASE1 |
| NCT05594602 | COMPLETED | COVID-19 |
Enanta Pharmaceuticals, Inc |
2022-10-06 | PHASE1 |
| NCT07542847 | COMPLETED | Healthy Volunteers |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2022-09-19 | PHASE1 |
| NCT05486949 | COMPLETED | Healthy Subjects |
Dizal Pharmaceuticals |
2022-07-27 | PHASE1 |
| NCT05248945 | COMPLETED | Healthy |
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
2022-01-13 | PHASE1 |
| NCT04923659 | ACTIVE_NOT_RECRUITING | Low Intensity Focussed Ultrasound |
University Health Network, Toronto |
2021-05-25 | EARLY_PHASE1 |
| NCT04330248 | COMPLETED | Healthy |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2020-03-31 | PHASE1 |
| NCT05418582 | COMPLETED | Healthy Subjects |
Dizal Pharmaceuticals |
2022-01-25 | PHASE1 |
| NCT05213481 | COMPLETED | Healthy |
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
2021-12-15 | PHASE1 |
| NCT05205447 | TERMINATED | Healthy |
Eli Lilly and Company |
2022-01-05 | PHASE1 |
| NCT04840888 | COMPLETED | Healthy |
Eli Lilly and Company |
2021-04-26 | PHASE1 |
| NCT04996199 | UNKNOWN | Trigeminal Neuralgia |
Postgraduate Institute of Dental Sciences Rohtak |
2021-09-18 | PHASE4 |
| NCT05028608 | COMPLETED | Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men |
Bayer |
2021-09-06 | PHASE1 |
| NCT04962230 | COMPLETED | Healthy Participant |
Pfizer |
2021-07-15 | PHASE1 |
| NCT04783753 | COMPLETED | Hepatitis B |
Enanta Pharmaceuticals, Inc |
2020-11-05 | PHASE1 |
| NCT04784000 | COMPLETED | Healthy Volunteer Study |
Atea Pharmaceuticals, Inc. |
2021-03-01 | PHASE1 |
| NCT03580317 | COMPLETED | Trigeminal Neuralgia |
Zhejiang Chinese Medical University |
2018-07-12 | |
| NCT04610879 | TERMINATED | Rolandic Epilepsy |
King's College London |
2019-08-02 | PHASE4 |
| NCT04967326 | COMPLETED | Epilepsy |
Gia Dinh People Hospital |
2016-01-01 | PHASE4 |
| NCT03161509 | TERMINATED | Bariatric Surgery Candidate |
Rambam Health Care Campus |
2017-07-01 | PHASE4 |
| NCT02623504 | TERMINATED | Bipolar Disorder |
Validus Pharmaceuticals |
2016-10-24 | PHASE4 |
| NCT02707965 | COMPLETED | Epilepsy |
Food and Drug Administration (FDA) |
2017-06-08 | PHASE1 |
| NCT02912364 | COMPLETED | Epilepsy |
Stanford University |
2016-07 | PHASE4 |
| NCT02374567 | TERMINATED | Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders |
Hannover Medical School |
2015-01 | PHASE3 |
| NCT02705768 | COMPLETED | Seizures, Focal |
All India Institute of Medical Sciences, Bhubaneswar |
2016-04 | PHASE4 |
| NCT01379469 | TERMINATED | Alpha-1-antitrypsin Deficiency; Liver Cirrhosis |
Washington University School of Medicine |
2012-01 | PHASE2 |
| NCT01465997 | COMPLETED | Epilepsy; Monotherapy |
UCB BIOSCIENCES GmbH |
2012-05 | PHASE3 |
| NCT02214615 | COMPLETED | Erythromelalgia |
VA Connecticut Healthcare System |
2014-04 | PHASE4 |
| NCT01954121 | COMPLETED | Epilepsy; Partial Seizures |
UCB Pharma SA |
2013-09 | PHASE3 |
| NCT01243177 | COMPLETED | Epilepsy; Monotherapy |
UCB BIOSCIENCES GmbH |
2011-04 | PHASE3 |
| NCT02870283 | COMPLETED | Bipolar Disorder |
Federal University of Rio Grande do Sul |
2010-05 | PHASE4 |
| NCT02132897 | COMPLETED | Bio-equivalence Study; Fed Conditions |
Center for Clinical Pharmacology Research Bdbeq S.A. |
2014-05 | PHASE1 |
| NCT01530022 | COMPLETED | Healthy |
UCB Pharma |
2012-05 | PHASE1 |
| NCT01967771 | COMPLETED | Infection, Human Immunodeficiency Virus |
ViiV Healthcare |
2013-10 | PHASE1 |
| NCT02208492 | COMPLETED | Focal Epilepsy |
Yonsei University |
2011-09 | PHASE4 |
| NCT00621751 | COMPLETED | Traumatic Brain Injury |
Wake Forest University Health Sciences |
2008-02 | |
| NCT01375374 | TERMINATED | Epilepsy, Partial |
UCB Pharma |
2011-07 | PHASE3 |
| NCT01128959 | COMPLETED | Epilepsy |
Lundbeck LLC |
2010-06 | PHASE3 |
| NCT01707407 | COMPLETED | Pharmacology, Clinical; Healthy |
Celgene |
2012-09-01 | PHASE1 |
| NCT01629368 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2012-06 | PHASE1 |
| NCT01635829 | COMPLETED | Healthy Participants |
Janssen Infectious Diseases BVBA |
2012-05 | PHASE1 |
| NCT01382017 | COMPLETED | Healthy Male Volunteers |
University of Kiel |
2011-06 | |
| NCT00976794 | COMPLETED | Bipolar I Disorder |
University of Sao Paulo |
2009-01 | PHASE4 |
| NCT00807989 | COMPLETED | Epilepsy |
Yonsei University |
2008-03 | PHASE4 |
| NCT01581918 | UNKNOWN | Chemotherapy-induced Nausea and Vomiting |
Faculdade de Medicina do ABC |
2011-12 | PHASE2 |
| NCT01365403 | COMPLETED | Healthy Volunteer |
Hoffmann-La Roche |
2011-04 | PHASE1 |
| NCT00848549 | COMPLETED | Epilepsy |
Eisai Inc. |
2008-10 | PHASE3 |
| NCT00894010 | COMPLETED | Photosensitive Epilepsy |
The Epilepsy Study Consortium |
2009-05 | PHASE2 |
| NCT00952432 | UNKNOWN | Carpal Tunnel Syndrome; Multiple Excitability Test |
Taipei Medical University WanFang Hospital |
2009-05 | |
| NCT00477295 | COMPLETED | Epilepsy |
Eisai Inc. |
2007-05 | PHASE3 |
| NCT00438451 | COMPLETED | Focal Epilepsy |
Johannes Gutenberg University Mainz |
2007-01 | PHASE4 |
| NCT01089855 | COMPLETED | Neuropathic Pain |
Novartis |
2009-12 | PHASE4 |
| NCT02284854 | COMPLETED | Epilepsy |
Bial - Portela C S.A. |
2009-07 | PHASE1 |
| NCT00294892 | COMPLETED | HIV Infections |
Radboud University Medical Center |
2006-02 | PHASE2 |
| NCT00542802 | UNKNOWN | Epileptic Seizures; Stroke |
Scienze Neurologiche Ospedaliere |
2007-09 | PHASE3 |
| NCT01127256 | COMPLETED | Epilepsy |
Eisai Korea Inc. |
2006-05-31 | PHASE4 |
| NCT00266630 | COMPLETED | Manic or Mixed Episode Associated With Bipolar I Disorder |
Eli Lilly and Company |
2005-11 | PHASE3 |
| NCT01079351 | COMPLETED | Epilepsy |
Lundbeck LLC |
2007-04 | PHASE1 |
| NCT00896987 | COMPLETED | Epilepsy |
Korean Epilepsy Society |
2006-05 | PHASE4 |
| NCT00913107 | COMPLETED | Trigeminal Neuralgia |
University of Malaya |
2007-09 | PHASE2; PHASE3 |
| NCT00175903 | COMPLETED | Epilepsy |
UCB Pharma |
2005-02 | PHASE3 |
| NCT00350857 | COMPLETED | Bipolar I Disorder |
Validus Pharmaceuticals |
2006-07 | PHASE4 |
| NCT00181870 | COMPLETED | Bipolar Disorder; Mania |
Massachusetts General Hospital |
2005-07 | PHASE4 |
| NCT00203567 | COMPLETED | Bipolar Depression |
Tuscaloosa Research & Education Advancement Corporation |
2005-08 | PHASE4 |
| NCT00260247 | COMPLETED | Metabolic Clearance Rate |
Odense University Hospital |
2005-04 | PHASE4 |
| NCT02253849 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-11 | PHASE1 |
| NCT00150787 | COMPLETED | Epilepsy, Tonic-clonic |
UCB Pharma |
2003-07 | PHASE3 |
| NCT00150735 | COMPLETED | Generalized Epilepsy |
UCB Pharma |
2002-06 | PHASE3 |
| NCT00000242 | COMPLETED | Cocaine-Related Disorders; Substance-Related Disorders |
Medical University of South Carolina |
1992-10-01 | PHASE2 |
| NCT00000217 | COMPLETED | Cocaine-Related Disorders; Substance-Related Disorders |
University of Kansas |
1990-09 | PHASE2 |
| NCT00000191 | COMPLETED | Cocaine-Related Disorders |
University of Pennsylvania |
1991-01 | PHASE2 |
| NCT00208520 | UNKNOWN | Adults With Tonic Clonic Seizures and/or Partial Seizures |
Dutch Epilepsy Clinics Foundation |
2003-07 | |
| NCT00150605 | COMPLETED | Bipolar Disorder |
Validus Pharmaceuticals |
2005-02 | PHASE3 |
| NCT00000441 | COMPLETED | Alcoholism |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
PHASE4 | |
| NCT00216567 | COMPLETED | Epilepsy, Rolandic |
Janssen Korea, Ltd., Korea |
2002-12 | PHASE4 |
| NCT00381537 | COMPLETED | Epilepsy |
Institute of Child Health |
||
| NCT00007670 | COMPLETED | Seizures |
US Department of Veterans Affairs |
1998-01 | PHASE3 |
| NCT00153296 | COMPLETED | Bronchial Asthma |
Centre of Chinese Medicine, Georgia |
2004-08 | PHASE4 |
| NCT00892125 | COMPLETED | Schizophrenia; Bipolar Disorder |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2006-09 | PHASE1 |
| NCT00000218 | COMPLETED | Cocaine-Related Disorders; Substance-Related Disorders |
National Institute on Drug Abuse (NIDA) |
PHASE4 | |
| NCT00006395 | COMPLETED | Healthy |
National Institutes of Health Clinical Center (CC) |
2000-10 | PHASE4 |
| NCT00150553 | COMPLETED | Bipolar Disorder |
Validus Pharmaceuticals |
2005-01 | PHASE3 |
| NCT00236717 | COMPLETED | Epilepsy; Seizures |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
1997-09 | PHASE3 |
| NCT00004758 | COMPLETED | Spasms, Infantile; Epilepsy |
National Center for Research Resources (NCRR) |
1993-11 | PHASE2 |
| NCT00325286 | UNKNOWN | Bipolar Disorder |
Creighton University |
2006-05 | PHASE4 |
| NCT00190892 | COMPLETED | Bipolar Disorder |
Eli Lilly and Company |
2004-09 | PHASE4 |
| NCT00207428 | COMPLETED | Bronchial Asthma |
Centre of Chinese Medicine, Georgia |
1999-08 | PHASE4 |
(data from https://clinicaltrials.gov, updated on 2026-06-29)
Check the
Carbamazepine
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.